课题基金 / 基金详情

Novel signal transduction pathways in constitutive active mutants of receptor tyrosine kianses

Novel signal transduction pathways in constitutive active mutants of receptor tyrosine kianses
受体酪氨酸激酶组成型活性突变体的新信号转导途径
批准号:
18591058
负责人:
MIZUKI Masao
金额:
$2.49万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

MIZUKI Masao的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Constitutive active mutants of receptor tyrosine kinases such as c-Kit and FLT3 have been identified as the frequent genetic abnormalities in acute myeloid leukemia, which serve as possible therapeutic targets. We have made a series of single Tyr-Phe mutants of c-Kit and FLT3, either wild type or active mutants, and analysed the critical signal transduction pathways which lead to cell function and oncogenic transformation. By analyzing the Tyr-Phe mutations of each 22 tyrosine residue of c-Kit, we have identified that Tyr567, Tyr569, and Tyr719 are the critical tyrosine residues which regulated the chemotactic function of c-Kit. Tyr567 and Tyr719 activates Src family kinases (SFK) and PI3K respectively, which cooperatively regulate the c-Kit/SCF mediated chemotaxis. By analyzing Gab2 (-/-) mast cells, we find that Gab2 is required for SCF-evoked proliferation, activation of Rac/JNK, and Ras. In wild type c-Kit, Tyr567 mediates SFK binding, and SFK activity was required for Gab2 tyrosyl phosphorylation and association with Shp-2. Thus, we find that Gab2, which is the downstream signaling intermediate of Tyr567, regulates c-Kit/SCF-mediated cellular function. In constitutive active mutants, STAT3/5 is highly activated compared to wild type. The mechanism of this aberrant activation has not been clarified. As FLT3 has three consensus STAT3 binding motifs in cytoplasmic domain, we have analysed the involvement of these tyrosine residues in the activation of STAT3 by FLT3 Asp835Val. In FLT3 Asp835Val, the Tyr-Phe conversion of these three tyrosine residues diminished, but not completely abolished the STAT3 activation. This result suggests that in constitutive active mutants of receptor tyrosine kinases, the aberrant STAT activation still partially depends on the binding to the consensus motif sequence, but also on the surrogate activation pathways such as src familily kinase pathways, which may be mediated by the juxtamembrane region and Gab2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis
内淋巴积水是复发性多软骨炎听觉前庭表现的原因
DOI: --
发表时间: 2006
期刊: Acta Otolaryngol 126・5
影响因子: --
作者: [宮崎正輝, 宮崎和子, 山崎憲政, 菅野雅元, 本田浩章, Murata J. et al.]
通讯作者: Murata J. et al.
腫瘍性チロシンキナーゼによる病型決定機構:FIP1L1/PDGFRαによる好酸球系細胞への選択的誘導.
肿瘤酪氨酸激酶的疾病类型判定机制:FIP1L1/PDGFRα选择性诱导嗜酸性细胞。
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Nakagawa, K., et al., Masuta Y., 福島健太郎]
通讯作者: 福島健太郎
DOI: --
发表时间: 2007
期刊: 癌と化学療法 34
影响因子: --
作者: [近藤 礎, 水木満佐央, 他]
通讯作者:
DOI: 10.1111/j.1349-7006.2007.00717.x
发表时间: 2008-03
期刊: Cancer Science
影响因子: 5.7
作者: [I. Matsumura;M. Mizuki;Y. Kanakura]
通讯作者: I. Matsumura;M. Mizuki;Y. Kanakura
12
    Analysis of weak points in oncogenic tyrosine kinase-dependent growth
    • 批准号:
      22591036
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2010
    • 负责人:
      MIZUKI Masao
    • 依托单位:
    Mechanism of leukemogenesis by constitutive active receptor tyrosine kinase
    • 批准号:
      16590938
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2004
    • 负责人:
      MIZUKI Masao
    • 依托单位:
    国内基金
    海外基金
    USP43-SAFB1轴调控FLT3突变急性髓系白血病细胞对FLT3抑制剂耐药的机制研究
    • 批准号:
      JCZRQNB202600664
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    靶向CASP1/GSDMD通路抑制FLT3突变阳性 AML患者耗竭性γ δ T细胞焦亡的机制研 究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2025
    • 负责人:
      金真伊
    • 依托单位:
    FLT3调控结肠癌细胞膜MHCI稳定性的机制及干预策略研究
    • 批准号:
      D25H300004
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      丁玲
    • 依托单位:
    新型小分子FLT3抑制剂STI-8591在FLT3突变急性髓系白血病中的应用及机制研究
    • 批准号:
      MS25H080016
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      张仪
    • 依托单位: